X‑37

Drug development at the speed of AI

First Investment: 2018

X‑37 aims to use AI to accelerate small-molecule drug discovery. The company’s seasoned chemists, biologists, and data scientists use machine learning algorithms to identify chemicals with drug-like structures, predict whether they might bind to biological targets, and weed out those likely to have unwanted properties.

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery